• About
    • About Us
    • Leadership
  • Investors
    • Overview
    • Press Releases
    • Governance
    • SEC Filings
    • Stock Info
    • Email Alerts
  • Contact

Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment

by B2i | Nov 4, 2020 | Press Releases

ROCKVILLE, Md., Nov. 4, 2020 — Shuttle Pharmaceuticals, Inc (Shuttle Pharma) a clinical stage, Maryland-based, biopharmaceutical company developing new drugs for cancer treatment in combination with radiation therapy, was awarded patent number 10,745,352 by the...
Next Entries »

Recent Posts

  • Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
  • United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation
  • Shuttle Merges with United Dogecoin to Become the World’s Largest Public Dogecoin Miner
  • RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
  • Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Recent Comments

No comments to show.

Contact

Shuttle Pharmaceuticals
401 Professional Drive
Suite 260
Gaithersburg, MD 20879

info@shuttlepharma.com

  • Follow
  • Follow
Sign up for Alerts

Site Links

  • Home
  • Investors
  • Privacy Policy
  • Contact

Our Company

  • About us
  • Leadership
© Copyright 2026 Shuttle Pharmaceuticals - All rights reserved
We use cookies to monitor and analyze how our site is used. By using our site, you agree to our use of cookies.